Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma

Biological Chemistry

Volumn 388, Issue 11, 2007, Pages 1235-1242

  Chee, Jessica ^a   Singh, Jasmine ^a   Naran, Anupam ^b   Misso, Neil L ^a   Thompson, Philip J ^a   Bhoola, Kanti D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Kallikrein related peptidases; Kinin B1 and B2 receptors; Plasma kallikrein; Pleural mesothelioma; Tissue kallikrein

Indexed keywords

ASBESTOS FIBER; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE; KININ; KININ B1 RECEPTOR; KININ B2 RECEPTOR; KININ RECEPTOR; PEPTIDASE; PEROXIDASE; PLASMA KALLIKREIN; RECEPTOR; RECEPTOR SUBTYPE; SERINE PROTEINASE; TISSUE KALLIKREIN; TISSUE KALLIKREIN 2; TISSUE KALLIKREIN 5; TISSUE KALLIKREIN 6; TISSUE KALLIKREIN 7; TISSUE KALLIKREIN 8; TISSUE KALLIKREIN 9; UNCLASSIFIED DRUG;

CANCER CELL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOPLASM; EPITHELIOID CELL; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; KALLIKREINS; KININS; MESOTHELIOMA; PEPTIDE HYDROLASES; PLEURAL NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 35848937305     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2007.139     Document Type: Conference Paper

References (47)

1. Akita, K., Okuno, M., Enya, M., Imai, S., Moriwaki, H., Kawada, N., Suzuki, Y., and Kojima, S. (2002). Impaired liver regeneration in mice by lipopolysaccharide via TNF-α/kallikrein-mediated activation of latent TGF-β. Gastroenterology 12, 35-36.
2. Bernett, M.J., Blaber, S.I., Scarisbrick, I.A., Dhanarajan, P., Thompson, S.M., and Blaber, M. (2002). Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277, 24562-24570.
3. Bhoola, K.D. and Fink, E. (2005). Kallikrein-kinin cascade. In: Encyclopedia of Respiratory Medicine, Vol. 2, G.J. Laurent and S.D. Shapiro, eds. (Oxford, UK: Elsevier Ltd.), pp. 483-493.
4. Bhoola, K.D., Figueroa, C.D., and Worthy, K. (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 84, 1-80.
5. Bhoola, K.D., Ramsaroop, R., Plendl, J., Cassim, B., Dlamini, Z., and Naicker, S. (2001). Kallikrein and kinin receptor expression in inflammation and cancer. Biol. Chem. 382, 77-89.
6. Bhoola, K.D., Misso, N.L., Naran, A., and Thompson, P.J. (2007). Current status of tissue kallikrein inhibitors: importance in cancer. Curr. Opin. Invest. Drugs 8, 462-468.
7. Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
8. Brambilla, E., Travis, W.D., Colby, T.V., Corrin, B., and Shimosato, Y. (2001). The new World Health Organization classification of lung tumours. Eur. Respir. J. 18, 1059-1068.
9. Cagle, P.T., Truong, L.D., Roggli, V.L., and Greenberg, S.D. (1989). Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms. Am. J. Clin. Pathol. 92, 566-571.
10. Clements, J., Hooper, J., Dong, Y., and Harvey, T. (2001). The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol. Chem. 382, 5-14.
11. Clements, J.A., Willemsen, N.M., Myers, S.A., and Dong, Y. (2004). The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41, 265-312.
12. Davidson, B., Zhijun, X., and Saatcioglu, F. (2007). Kallikrein 4 is expressed in malignant mesothelioma - further evidence for the histogenetic link between mesothelial and epithelial cells. Diagn. Cytopathol. 35, 80-84.
13. Egelrud, T. and Lundstrom, A. (1991). A chymotrypsin-like proteinase that may be involved in desquamation in plantar stratum corneum. Arch. Dermatol. Res. 283, 108-112.
14. Fink, E., Bhoola, K.D., Snyman, C., Neth, P., and Figueroa, C.D. (2007). Cellular expression of plasma prekallikrein in human tissues. Biol. Chem. 388, 957-963.
15. Frenette, G., Tremblay, R.R., Lazure, C., and Dube, J.Y. (1997) Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 71, 897-899.
16. Fritzsche, F., Gansukh, T., Borgono, C.A., Burkhardt, M., Pahl, S., Mayordomo, E., Winzer, K.J., Weichert, W., Denkert, C., Jung, K., et al. (2006). Expression of human kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. Br. J. Cancer 94, 540-547.
17. Harvey, T.J., Hooper, J.D., Myers, S.A., Stephenson, S.A., Ashworth, L.K., and Clements, J.A. (2000) Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem. 275, 37397-37406.
18. Hecquet, C., Tan, F., Marcic, B.M., and Erdos, E.G. (2000). Human bradykinin B2 receptor is activated by kallikrein and other serine proteases. Mol. Pharmacol. 58, 828-836.
19. Hodgson, J.T. and Darnton, A. (2000). The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann. Occup. Hyg. 44, 565-601.
20. Iwata, A., Maruyama, M., Akagi, T., Hashikawa, T., Kanazawa, I., Tsuji, S., and Nukina, N. (2003). Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum. Mol. Genet. 12, 2625-2635.
21. Janssen, S., Rosen, D.M., Ricklis, R.M., Dionne, C.A., Lilja, H., Christensen, S.B., Isaacs, J.T., and Denmeade, S.R. (2006). Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate 66, 358-368.
22. Lundwall, A., Band, V., Blaber, M., Clements, J.A., Courty, Y., Diamandis, E.P., Fritz, H., Lilja, H., Malm, J., Maltais, L.J., et al. (2006). A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 387, 637-641.
23. Maeda, H., Fang, J., Inutsuka, T., and Kitamoto, Y. (2003). Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3, 319-328.
24. Mahabeer, R. and Bhoola, K.D. (2000). Kallikrein and kinin receptor genes. Pharmacol. Ther. 88, 77-89.
25. Matsumura, Y., Kimura, M., Yamamoto, T., and Maeda, H. (1988). Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79, 1327-1334.
26. Neth, P., Arnhold, M., Nitschko, H., and Fink, E. (2001). The mRNAs of prekallikrein, factors XI and XII, and kininogen, components of the contact phase cascade are differentially expressed in multiple non-hepatic tissues. Thromb. Haemost. 85, 1043-1047.
27. Nylander-Lundqvist, E. and Egelrud, T. (1997). Formation of active IL-1β from pro-IL-1β catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta Derm. Venereol. 77, 203-206.
28. Obiezu, C.V. and Diamandis, E.P. (2005). Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 224, 1-22.
29. Ogawa, K., Yamada, T., Tsujioka, Y., Taguchi, J., Takahashi, M., Tsuboi, Y., Fujino, Y., Nakajima, M., Yamamoto, T., Akatsu, H., et al. (2000). Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin. Neurosci. 54, 419-426.
30. Okui, A., Kominami, K., Uemura, H., Mitsui, S., and Yamaguchi, N. (2001). Characterization of a brain-related serine protease, neurosin (human kallikrein 6), in human cerebrospinal fluid. Neuroreport 12, 1345-1350.
31. Peek, M., Moran, P., Mendoza, N., Wickramasinghe, D., and Kirchhofer, D. (2002). Unusual proteolytic activation of prohepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J. Biol. Chem. 277, 47804-47809.
32. Petraki, C.D., Papanastasiou, P.A., Karavana, V.N., and Diamandis, E.P. (2006). Cellular distribution of human tissue kallikreins: immunohistochemical localization. Biol. Chem. 387, 653-663.
33. Plendl, J., Snyman, C., Naidoo, S., Sawant, S., Mahabeer, R., and Bhoola, K.D. (2000). Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol. Chem. 381, 1103-1115.
34. Rhehault, S., Monget, P., Mazerbourg, S., Tremblay, R., Gutman, N., Gauthier, F., and Moreau, I. (2001). Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur. J. Biochem. 268, 2960-2968.
35. Rittenhouse, H.G., Finlay, J.A., Mikolajczyk, S.D., and Partin, A.W. (1998). Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci. 35, 275-368.
36. Roberts, R.A. and Gullick, W.J. (1989). Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. J. Cell Sci. 94, 527-535.
37. Selvarajan, S., Lund, L.R., Takeuchi, T., Craik, C.S., and Werb, Z. (2001). A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat. Cell Biol. 3, 267-275.
38. Simon, M., Jonca, N., Guerrin, M., Haftek, M., Bernard, D., Caubet, C., Egelrud, T., Schmidt, R., and Serre, G. (2001). Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J. Biol. Chem. 276, 20292-20299.
39. Stephenson, S.A., Verity, K., Ashworth, L.K., and Clements, J.A. (1999). Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J. Biol. Chem. 274, 23210-23214.
40. Tan, O.L., Whitbread, A.K., Clements, J.A., and Dong, Y. (2006). Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? Biol. Chem. 387, 697-705.
41. Tang, J., Yu, C.L., Williams, S.R., Springman, E., Jeffery, D., Sprengeler, P.A., Estevez, A., Sampang, J., Shrader, W., Spencer, J., et al. (2005). Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein. J. Biol. Chem. 280, 41077-41089.
42. Travis, W.D., Brambilla, E., Müller-Hermelink, H.K., and Harris, C.C. (2004). Pathology and genetics of tumours of the lung, pleura, thymus and heart. In: World Health Organization Classification of Tumours (Lyon, France: IARC Press), pp. 1-334.
43. Tschesche, H., Michaelis, J., Kohnert, U., Fedrowitz, J., and Oberhoff, R. (1989). Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. Adv. Exp. Med. Biol. 247A, 545-548.
44. Wolf, W.C., Evans, M.D., Chao, L., and Chao, J. (2001). A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am. J. Pathol. 159, 1797-1805.
45. Wu, J., Akaike, T., Hayashida, K., Miyamoto, Y., Nakagawa, T., Miyakawa, K., Müller-Esterl, W., and Maeda, H. (2002). Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int. J. Cancer 98, 29-35.
46. Yousef, G.M. and Diamandis, E.P. (2000). The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics 65, 184-194.
47. Yousef, G.M. and Diamandis, E.P. (2001). The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184-204.